New study shows that in multiple system atrophy, sleep disorders are a common but scarcely studied symptom associated with disease severity Unusual diseases are medical mysteries that fascinate us, ...

Multiple system atrophy (MSA) is a rare neurological disorder. It causes nerve cells in parts of your brain to gradually decline. Over time, this damage affects your body’s involuntary processes.

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

White arrows indicate accumulation of 18F-SPAL-T-06, suggesting α-synuclein aggregates in the putamen, yellow arrows in the pons, yellow triangle in the cerebellar white matter, and white triangle in ...

Please provide your email address to receive an email when new articles are posted on . Multiple system atrophy — whose worldwide awareness day is commemorated every Oct. 3 — includes disorders that ...

The diagnosis of MSA can be challenging because its initial symptoms resemble those of other diseases. MSA can only be conclusively diagnosed through examination of the brain and nervous system. A ...

Multiple system atrophy (MSA) is a neurodegenerative disease that affects involuntary body functions such as blood pressure and heart rate as well as movement. It is similar to Parkinson's disease, ...

The Food and Drug Administration (FDA) has granted Fast Track designation to verdiperstat (BVH-3241; Biohaven) for the treatment of multiple system atrophy. The Food and Drug Administration (FDA) has ...

This pilot open label study investigated the safety and preliminary efficacy of using IVIG over a 6-month period for treatment of MSA. IVIG treatment was well tolerated. Post-treatment functional ...